Back to resultsLong-term Safety Study of Chronocort in the Treatment of Participants With Congenital Adrenal Hyperplasia
Primary Purpose
Congenital Adrenal Hyperplasia
Status
Enrolling by invitation
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Chronocort
Sponsored by
About this trial
This is an interventional treatment trial for Congenital Adrenal Hyperplasia focused on measuring Extension study
Eligibility Criteria
Inclusion Criteria:
- Participants with Congenital adrenal hyperplasia (CAH), in eligible countries who have successfully completed one of the specified previous Chronocort studies (DIUR-006 or DIUR-014).
- Participants who are capable of giving signed informed consent/assent.
Exclusion Criteria:
- Participants with clinical or biochemical evidence of hepatic or renal disease e.g., creatinine >2 times the upper limit of normal (ULN) or elevated liver function tests (alanine aminotransferase [ALT] or aspartate aminotransferase [AST] >2 times the ULN).
- Participants with a history of malignancy (other than basal cell carcinoma successfully treated >26 weeks prior to entry into the study).
- Participants with a history of bilateral adrenalectomy.
- Participants with any other significant medical or psychiatric conditions that in the opinion of the Investigator would preclude participation in the study.
- Participants with a co-morbid condition requiring daily administration of a medication or consumption of any material that interferes with the metabolism of glucocorticoids.
- Participants on regular daily inhaled, topical, nasal, or oral steroids for any indication other than CAH.
- Participants anticipating regular prophylactic use of additional steroids e.g., for strenuous exercise.
- Participation in another clinical study of an investigational or licensed drug or device within 3 months prior to inclusion in this study, except for another clinical study with the current formulation of Chronocort.
- Females who are pregnant or lactating.
- Participants, who in the opinion of the Investigator, will be unable to comply with the requirements of the protocol.
- Participants who routinely work night shifts and so do not sleep during the usual night-time hours.
- Participants with a body weight of 50 kg or less.
Sites / Locations
- National Institutes of Health Center
- Diurnal investigational Site in Lyon
- Diurnal Investigational Site in Paris
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Chronocort (hydrocortisone modified-release capsule)
Arm Description
Chronocort (hydrocortisone modified-release capsules) supplied as 5 mg and 10 mg per capsule for oral administration.
Outcomes
Primary Outcome Measures
To measure signs or symptoms of under treatment [Safety and Tolerability] in terms of incidence of adrenal crises throughout the study.
Occurrence of adrenal crises throughout the study.
Signs and symptoms of under-treatment [Safety and Tolerability] throughout the study.
Under-replacement normally presents with acute effects such as sudden weight loss, lack of appetite, nausea, vomiting, headache, blurred vision, fatigue, weakness, dizziness, light-headedness and syncope.
To measure signs or symptoms of under treatment [Safety and Tolerability] in terms of use of additional glucocorticoid treatment throughout the study.
Use of Immediate Release Hydrocortisone (IRHC) from the emergency packs for stress dosing or use of any additional glucocorticoid treatment.
Signs and symptoms of over-treatment [Safety and Tolerability] throughout the study.
Over-replacement normally presents with chronic effects such as weight gain, increased appetite, sleeping difficulties, increased acne and Cushingoid syndrome.
To measure the incidence of Treatment-Emergent Adverse Events [Safety and Tolerability].
The incidence, nature, severity, relatedness, duration, outcome, seriousness, and expectedness of treatment-emergent adverse events (TEAEs) throughout the study.
To measure the change from pre-Chronocort baseline in terms of hematology safety laboratory assessments [Safety and Tolerability].
Lab parameters will be summarized and compared throughout the study as follows:
Platelet count, Red blood cell count (RBC), Haemoglobin, Haematocrit, RBC Indices: Mean corpuscular volume (MCV), Mean cell haemoglobin (MCH). Mean cell haemoglobin concentration (MCHC), Red cell distribution width (RDW).
White blood cell (WBC) count with differential (absolute and %): Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils.
To measure the change from pre-Chronocort baseline in terms of clinical chemistry safety laboratory assessments [Safety and Tolerability].
To measure the change from pre-Chronocort baseline in terms of clinical chemistry safety laboratory assessments [Safety and Tolerability].
Blood urea nitrogen (BUN), Creatinine, Chloride, Total magnesium, Potassium, Sodium, Calcium, Total carbon dioxide (CO2), Inorganic phosphorus, AST/serum glutamic-oxaloacetic transaminase (SGOT), ALT/serum glutamic-pyruvic transaminase (SGPT), Alkaline phosphatase, Albumin, Total and direct bilirubin, Total protein, Lactate dehydrogenase (LDH), Total creatine kinase (CK), Uric acid.
To measure the change from pre-Chronocort baseline in terms of vital signs assessments.
Blood pressure measurements throughout the study will be summarised and compared.
Secondary Outcome Measures
To assess the impact of treatment on dose of steroid required.
Change from pre-Chronocort baseline in total daily steroid dose in hydrocortisone equivalent dose at each visit.
To assess the impact of treatment on 17-Hydroxyprogesterone (17-OHP) levels.
Change in 17-OHP levels from pre Chronocort baseline at each visit.
To assess the impact of treatment on Androstenedione (A4) levels.
Change in A4 levels from pre-Chronocort baseline at each visit.
To assess the impact of treatment on menstrual regularity (recorded in a participant diary) as a marker of fertility.
Change from pre-Chronocort baseline in menstrual regularity as recorded in a participant diary. With menstrual regularity defined as a cycle (menstrual bleeding) occurring every 21 to 35 days (only in pre-menopausal females without hysterectomy and not using hormonal contraceptives).
To assess the impact of treatment on luteinising hormone (LH) levels in men as a marker of fertility.
Change from pre-Chronocort baseline in luteinising hormone (LH) levels throughout the study.
To assess the impact of treatment on testosterone by sex.
Change in testosterone levels from pre-Chronocort baseline through the study, summarized by gender.
To assess the impact of treatment on waist circumference.
Change from pre-Chronocort baseline to each visit in waist circumference.
To assess the impact of treatment on body weight.
Change from pre-Chronocort baseline to each visit in body weight.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05299554
Brief Title
Long-term Safety Study of Chronocort in the Treatment of Participants With Congenital Adrenal Hyperplasia
Official Title
A Phase 3 Open-Label Extension Study to Evaluate the Long-term Safety and Tolerability of Chronocort in the Treatment of Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia
Study Type
Interventional
2. Study Status
Record Verification Date
October 2022
Overall Recruitment Status
Enrolling by invitation
Study Start Date
April 1, 2022 (Actual)
Primary Completion Date
January 1, 2025 (Anticipated)
Study Completion Date
January 1, 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Diurnal Limited
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This phase III study is an open-label extension study to be conducted at approximately 36 investigational sites across 3 countries. The study will evaluate the long-term safety and tolerability of Chronocort in participants aged 16 years and over when used as treatment for Congenital Adrenal Hyperplasia (CAH).
Detailed Description
Participants in eligible countries completing one of the specified previous Chronocort studies (DIUR-006 and DIUR 014) can either continue Chronocort treatment (if the participant received Chronocort in the feeder study) or switch to Chronocort treatment (if the participant received standard glucocorticoid therapy in the feeder study) in this open-label extension study. All participants choosing to enter this extension study will have the study procedures fully explained and informed consent obtained, prior to, or at the last visit of the feeder study. Participants who agree to take part in this extension study will then undergo the final visit of the feeder study, with the assessments conducted at the final visit also providing the baseline data for this DIUR-015 extension study where relevant (note participants who are withdrawn from treatment due to titration issues in study DIUR-014 are eligible to enter at the discretion of the Investigator, as long as all DIUR-014 safety assessments and the end of study visit are completed). Once all the baseline assessments are completed, participants will be given sufficient Chronocort to use until the next visit (the study pharmacies will be supplied with Chronocort for dispensing to participants according to the Investigators' instructions).
Outcome measures in this study will be assessed versus either the 'initial study baseline' (measurements taken at the start of participation in an interventional Diurnal study, regardless of the treatment assignment in this feeder study) or the protocol-defined 'pre-Chronocort baseline' (measurements taken prior to the first dose of continuous Chronocort).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Congenital Adrenal Hyperplasia
Keywords
Extension study
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Model Description
Single arm extension study
Masking
None (Open Label)
Allocation
N/A
Enrollment
181 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Chronocort (hydrocortisone modified-release capsule)
Arm Type
Experimental
Arm Description
Chronocort (hydrocortisone modified-release capsules) supplied as 5 mg and 10 mg per capsule for oral administration.
Intervention Type
Drug
Intervention Name(s)
Chronocort
Other Intervention Name(s)
Hydrocortisone modified-release hard capsule
Intervention Description
Hydrocortisone modified-release capsule 5 mg and 10 mg
Primary Outcome Measure Information:
Title
To measure signs or symptoms of under treatment [Safety and Tolerability] in terms of incidence of adrenal crises throughout the study.
Description
Occurrence of adrenal crises throughout the study.
Time Frame
Up to 4 years.
Title
Signs and symptoms of under-treatment [Safety and Tolerability] throughout the study.
Description
Under-replacement normally presents with acute effects such as sudden weight loss, lack of appetite, nausea, vomiting, headache, blurred vision, fatigue, weakness, dizziness, light-headedness and syncope.
Time Frame
Up to 4 years.
Title
To measure signs or symptoms of under treatment [Safety and Tolerability] in terms of use of additional glucocorticoid treatment throughout the study.
Description
Use of Immediate Release Hydrocortisone (IRHC) from the emergency packs for stress dosing or use of any additional glucocorticoid treatment.
Time Frame
Up to 4 years.
Title
Signs and symptoms of over-treatment [Safety and Tolerability] throughout the study.
Description
Over-replacement normally presents with chronic effects such as weight gain, increased appetite, sleeping difficulties, increased acne and Cushingoid syndrome.
Time Frame
Up to 4 years.
Title
To measure the incidence of Treatment-Emergent Adverse Events [Safety and Tolerability].
Description
The incidence, nature, severity, relatedness, duration, outcome, seriousness, and expectedness of treatment-emergent adverse events (TEAEs) throughout the study.
Time Frame
Up to 4 years.
Title
To measure the change from pre-Chronocort baseline in terms of hematology safety laboratory assessments [Safety and Tolerability].
Description
Lab parameters will be summarized and compared throughout the study as follows:
Platelet count, Red blood cell count (RBC), Haemoglobin, Haematocrit, RBC Indices: Mean corpuscular volume (MCV), Mean cell haemoglobin (MCH). Mean cell haemoglobin concentration (MCHC), Red cell distribution width (RDW).
White blood cell (WBC) count with differential (absolute and %): Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils.
Time Frame
Up to 4 years.
Title
To measure the change from pre-Chronocort baseline in terms of clinical chemistry safety laboratory assessments [Safety and Tolerability].
Description
To measure the change from pre-Chronocort baseline in terms of clinical chemistry safety laboratory assessments [Safety and Tolerability].
Blood urea nitrogen (BUN), Creatinine, Chloride, Total magnesium, Potassium, Sodium, Calcium, Total carbon dioxide (CO2), Inorganic phosphorus, AST/serum glutamic-oxaloacetic transaminase (SGOT), ALT/serum glutamic-pyruvic transaminase (SGPT), Alkaline phosphatase, Albumin, Total and direct bilirubin, Total protein, Lactate dehydrogenase (LDH), Total creatine kinase (CK), Uric acid.
Time Frame
Up to 4 years.
Title
To measure the change from pre-Chronocort baseline in terms of vital signs assessments.
Description
Blood pressure measurements throughout the study will be summarised and compared.
Time Frame
Up to 4 years.
Secondary Outcome Measure Information:
Title
To assess the impact of treatment on dose of steroid required.
Description
Change from pre-Chronocort baseline in total daily steroid dose in hydrocortisone equivalent dose at each visit.
Time Frame
Up to 4 years.
Title
To assess the impact of treatment on 17-Hydroxyprogesterone (17-OHP) levels.
Description
Change in 17-OHP levels from pre Chronocort baseline at each visit.
Time Frame
Up to 4 years.
Title
To assess the impact of treatment on Androstenedione (A4) levels.
Description
Change in A4 levels from pre-Chronocort baseline at each visit.
Time Frame
Up to 4 years.
Title
To assess the impact of treatment on menstrual regularity (recorded in a participant diary) as a marker of fertility.
Description
Change from pre-Chronocort baseline in menstrual regularity as recorded in a participant diary. With menstrual regularity defined as a cycle (menstrual bleeding) occurring every 21 to 35 days (only in pre-menopausal females without hysterectomy and not using hormonal contraceptives).
Time Frame
Up to 4 years.
Title
To assess the impact of treatment on luteinising hormone (LH) levels in men as a marker of fertility.
Description
Change from pre-Chronocort baseline in luteinising hormone (LH) levels throughout the study.
Time Frame
Up to 4 years.
Title
To assess the impact of treatment on testosterone by sex.
Description
Change in testosterone levels from pre-Chronocort baseline through the study, summarized by gender.
Time Frame
Up to 4 years.
Title
To assess the impact of treatment on waist circumference.
Description
Change from pre-Chronocort baseline to each visit in waist circumference.
Time Frame
Up to 4 years.
Title
To assess the impact of treatment on body weight.
Description
Change from pre-Chronocort baseline to each visit in body weight.
Time Frame
Up to 4 years.
Other Pre-specified Outcome Measures:
Title
To assess the impact of treatment on the dose of steroid
Description
Change from initial study baseline in daily steroid dose as the hydrocortisone equivalent dose.
Time Frame
Up to 4 years.
Title
To assess the impact of treatment on 17-Hydroxyprogesterone (17-OHP) levels
Description
Change in 17-OHP levels from initial study baseline throughout the study.
Time Frame
Up to 4 years.
Title
To assess the impact of treatment on Androstenedione (A4) levels.
Description
Change in A4 levels from initial study baseline throughout the study.
Time Frame
Up to 4 years.
Title
To assess the impact of treatment on menstrual regularity (recorded in a participant diary) as a marker of fertility.
Description
Change from initial study baseline in menstrual regularity as recorded in a participant diary. With menstrual regularity defined as a cycle (menstrual bleeding) occurring every 21 to 35 days (only in pre-menopausal females without hysterectomy and not using hormonal contraceptives).
Time Frame
Up to 4 years.
Title
To assess the impact of treatment on luteinising hormone (LH) levels in men as a marker of fertility.
Description
Change from initial study baseline on luteinising hormone (LH) levels throughout the study.
Time Frame
Up to 4 years.
Title
To assess the impact of treatment on testosterone by sex.
Description
Change in testosterone from initial study baseline throughout the study, summarized by gender.
Time Frame
Up to 4 years.
Title
To assess the impact of treatment on waist circumference.
Description
Change from initial study baseline throughout the study in waist circumference.
Time Frame
Up to 4 years.
Title
To assess the impact of treatment on body weight.
Description
Change from initial study baseline throughout the study in body weight.
Time Frame
Up to 4 years.
Title
To measure the change from pre-Chronocort baseline in Quality of Life (QoL) using the EuroQol 5-level Standardized Health Questionnaire (EQ 5D-5L™).
Description
QoL will be summarized and compared throughout the study. The scale measures on a 5-component scale including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Where the minimum score is 0 and maximum score is 100, a high score indicates a more favorable outcome.
Time Frame
Up to 4 years.
Title
To measure the change from initial study baseline in Quality of Life (QoL) using the EuroQol 5-level Standardized Health Questionnaire (EQ 5D-5L™).
Description
QoL will be summarized and compared throughout the study. The scale measures on a 5-component scale including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Where the minimum score is 0 and maximum score is 100, a high score indicates a more favorable outcome.
Time Frame
Up to 4 years.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
16 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Participants with Congenital adrenal hyperplasia (CAH), in eligible countries who have successfully completed one of the specified previous Chronocort studies (DIUR-006 or DIUR-014).
Participants who are capable of giving signed informed consent/assent.
Exclusion Criteria:
Participants with clinical or biochemical evidence of hepatic or renal disease e.g., creatinine >2 times the upper limit of normal (ULN) or elevated liver function tests (alanine aminotransferase [ALT] or aspartate aminotransferase [AST] >2 times the ULN).
Participants with a history of malignancy (other than basal cell carcinoma successfully treated >26 weeks prior to entry into the study).
Participants with a history of bilateral adrenalectomy.
Participants with any other significant medical or psychiatric conditions that in the opinion of the Investigator would preclude participation in the study.
Participants with a co-morbid condition requiring daily administration of a medication or consumption of any material that interferes with the metabolism of glucocorticoids.
Participants on regular daily inhaled, topical, nasal, or oral steroids for any indication other than CAH.
Participants anticipating regular prophylactic use of additional steroids e.g., for strenuous exercise.
Participation in another clinical study of an investigational or licensed drug or device within 3 months prior to inclusion in this study, except for another clinical study with the current formulation of Chronocort.
Females who are pregnant or lactating.
Participants, who in the opinion of the Investigator, will be unable to comply with the requirements of the protocol.
Participants who routinely work night shifts and so do not sleep during the usual night-time hours.
Participants with a body weight of 50 kg or less.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
D Merke
Organizational Affiliation
National Instiututes of Health Clinical Centre, Bethesda, Maryland, United States, 20892-1932
Official's Role
Principal Investigator
Facility Information:
Facility Name
National Institutes of Health Center
City
Bethesda
State/Province
Maryland
ZIP/Postal Code
20892-1932
Country
United States
Facility Name
Diurnal investigational Site in Lyon
City
Lyon
ZIP/Postal Code
69677
Country
France
Facility Name
Diurnal Investigational Site in Paris
City
Paris
ZIP/Postal Code
75651
Country
France
12. IPD Sharing Statement
Learn more about this trial
Long-term Safety Study of Chronocort in the Treatment of Participants With Congenital Adrenal Hyperplasia
We'll reach out to this number within 24 hrs